Humana Has A 'Positive 6-Month Catalyst Path,' Says Bullish Analyst
Portfolio Pulse from Priya Nigam
Humana Inc (NYSE:HUM) has been rated Overweight by Piper Sandler's analyst Jessica Tassan, with a price target of $392. The company recently signed an in-network deal with UAB's Health System and is expected to raise its 2024 adjusted earnings guidance. New CEO Jim Rechtin's leadership is anticipated to accelerate the company's turnaround.
June 26, 2024 | 4:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Humana Inc has been rated Overweight by Piper Sandler's analyst Jessica Tassan, with a price target of $392. The company recently signed an in-network deal with UAB's Health System and is expected to raise its 2024 adjusted earnings guidance. New CEO Jim Rechtin's leadership is anticipated to accelerate the company's turnaround.
The Overweight rating and price target of $392 from Piper Sandler's analyst, along with the new in-network deal with UAB's Health System, are positive indicators for Humana. The anticipated leadership of new CEO Jim Rechtin and the expected raise in 2024 adjusted earnings guidance further support a positive short-term outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100